Registration Pathways
Overview
All medical devices require an NIE from Kemenkes before they can be distributed in Indonesia. The pathway a device follows depends on its risk classification and whether it has existing approvals from recognised international regulators. There is no equivalent of the EU's Notified Body or the US's 510(k) predetermined change control — every device undergoes individual evaluation by Kemenkes via the Regalkes portal.
Standard Pathway (All Classes)
The standard pathway applies to all devices regardless of classification. The process:
- LAR obtains IDAK + CDAKB certification (prerequisite)
- Manufacturer and LAR prepare the ASEAN CSDT dossier
- LAR submits through Regalkes
- Administrative review by Kemenkes (completeness check)
- PNBP fee payment triggered on passing administrative review
- Technical review by Kemenkes evaluators
- Clarification rounds (typically at least one)
- NIE issued on approval
Expedited / Supported Pathway
Indonesia does not have a formal expedited pathway equivalent to Singapore's ASEAN Harmonised review. However, existing approvals from major regulators can support and potentially speed up the Kemenkes technical review:
| Foreign Approval | Effect in Indonesia |
|---|---|
| US FDA 510(k) / PMA clearance | Can be submitted as supporting evidence; may reduce evaluator queries on safety/performance |
| EU CE Mark (MDR) | Accepted as supporting evidence; technical documentation aligned with MDR facilitates CSDT preparation |
| Australia TGA (ARTG) | Supporting evidence |
| Singapore HSA | Particularly useful given ASEAN alignment; CSDT from HSA can often be adapted with minimal rework |
| Malaysia MDA | Supporting evidence |
Foreign approval does not automatically guarantee NIE approval or waive any documentation requirements. A complete ASEAN CSDT dossier must still be submitted. Indonesian evaluators conduct an independent review. Foreign approvals reduce the risk of queries but do not replace the process.
Class-by-Class Pathway Summary
| Class | Dossier | Clinical Evidence | Review Time | Fee Level |
|---|---|---|---|---|
| A | Simplified | Not required | ~15–30 days | Low |
| B | Standard CSDT | Literature review | 3–6 months | Moderate |
| C | Full CSDT | Clinical evaluation report | 6–12 months | Higher |
| D | Full CSDT + enhanced | Full clinical data | 6–12+ months | Highest |
Product Grouping Strategy
Indonesia permits product grouping — registering multiple devices under a single NIE application where devices are sufficiently similar (same intended use, same technology, same manufacturer, minor variants in size/configuration). This can significantly reduce registration costs and timelines for manufacturers with large consumable portfolios.
Effective grouping requires:
- Devices to share the same brand/trade name
- Same basic design and intended use
- Variants limited to size, colour, or minor configuration (not different intended uses)
- A single dossier covering all variants with a clear variant table
Discuss grouping strategy with your LAR and regulatory consultant before submitting.
Re-Registration vs Variation
Not every change to a registered device requires a new NIE:
- Minor changes (address update, label layout, minor supplier change) → Change Notification (Perubahan) via Regalkes — faster and cheaper
- Major changes (new intended use, new brand name, change of NIE holder) → Full re-registration required
See Change Notifications for the decision framework.